AR066759A1 - Derivados de piperidina-amida - Google Patents

Derivados de piperidina-amida

Info

Publication number
AR066759A1
AR066759A1 ARP080102257A ARP080102257A AR066759A1 AR 066759 A1 AR066759 A1 AR 066759A1 AR P080102257 A ARP080102257 A AR P080102257A AR P080102257 A ARP080102257 A AR P080102257A AR 066759 A1 AR066759 A1 AR 066759A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
alkoxy
aryl
hydroxy
heteroaryl
Prior art date
Application number
ARP080102257A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR066759A1 publication Critical patent/AR066759A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos. Reivindicacion 1: Compuestos de la formula (1) en la que X es S e Y es CR3, o X es CR3 e Y es S; R1 es arilo o heteroarilo, dicho arilo o heteroarilo puede estar opcionalmente sustituido por 1-3 sustituyentes elegidos con independencia entre sí entre el grupo formado por halogeno, hidroxi, CN, alquilo inferior e hidroxi-alquilo inferior; R2 es arilo, heteroarilo o aril-alquilo inferior, dicho arilo o heteroarilo puede estar opcionalmente sustituido por 1-3 sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo inferior, halogeno, hidroxi, CN, NO2, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, S(O2)R4, C(O)R5, imidazolilo, pirazolilo, tetrazolilo, pirrolilo y NR6R7, dicho alquilo inferior o alcoxi inferior está opcionalmente o sustituido por hidroxi, COOH, carbamoilo, amino, halogeno o alcoxi inferior; R3 es hidrogeno, halogeno, CN, alquilo inferior, fluoralquilo inferior, alcoxi inferior, fluor-alcoxi inferior o alcoxi inferior-alquilo inferior; R4 es alquilo inferior o amino; R5 es hidrogeno, hidroxi, alquilo inferior, alcoxi inferior o amino; R6 y R7 con independencia entre sí son hidrogeno, alquilo inferior, alquilo inferior-carbonilo o alquilo inferior-SO2; y sus sales y ésteres farmacéuticamente aceptables.
ARP080102257A 2007-06-01 2008-05-29 Derivados de piperidina-amida AR066759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07109458 2007-06-01

Publications (1)

Publication Number Publication Date
AR066759A1 true AR066759A1 (es) 2009-09-09

Family

ID=39645621

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102257A AR066759A1 (es) 2007-06-01 2008-05-29 Derivados de piperidina-amida

Country Status (17)

Country Link
US (1) US8039487B2 (es)
EP (1) EP2155738B1 (es)
JP (1) JP5220848B2 (es)
KR (1) KR101140520B1 (es)
CN (1) CN101679404B (es)
AR (1) AR066759A1 (es)
AT (1) ATE518857T1 (es)
AU (1) AU2008257693B2 (es)
BR (1) BRPI0811978A2 (es)
CA (1) CA2689383C (es)
CL (1) CL2008001552A1 (es)
ES (1) ES2369315T3 (es)
IL (1) IL202159A (es)
MX (1) MX2009013003A (es)
PE (1) PE20090320A1 (es)
TW (1) TW200901997A (es)
WO (1) WO2008145596A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
CA2922703A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
AU2022269825A1 (en) * 2021-05-04 2023-11-09 2N Pharma Aps Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases
EP4370129A1 (en) * 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165519A1 (en) * 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
ATE466838T1 (de) * 2005-06-06 2010-05-15 Hoffmann La Roche Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
WO2007031429A1 (en) * 2005-09-15 2007-03-22 F. Hoffmann-La Roche Ag Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
RU2396269C2 (ru) 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
ES2432383T3 (es) * 2008-05-05 2013-12-03 Merck Patent Gmbh Derivados de nip-tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa
DE102008029734A1 (de) * 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate

Also Published As

Publication number Publication date
WO2008145596A1 (en) 2008-12-04
CA2689383C (en) 2013-10-08
EP2155738B1 (en) 2011-08-03
US20080300279A1 (en) 2008-12-04
ES2369315T3 (es) 2011-11-29
CN101679404A (zh) 2010-03-24
ATE518857T1 (de) 2011-08-15
IL202159A (en) 2013-07-31
CL2008001552A1 (es) 2009-05-22
AU2008257693B2 (en) 2011-01-27
IL202159A0 (en) 2010-06-16
JP2010529001A (ja) 2010-08-26
JP5220848B2 (ja) 2013-06-26
KR101140520B1 (ko) 2012-04-30
PE20090320A1 (es) 2009-03-19
AU2008257693A1 (en) 2008-12-04
EP2155738A1 (en) 2010-02-24
BRPI0811978A2 (pt) 2014-11-18
TW200901997A (en) 2009-01-16
MX2009013003A (es) 2010-01-20
KR20100017976A (ko) 2010-02-16
CN101679404B (zh) 2012-06-13
CA2689383A1 (en) 2008-12-04
US8039487B2 (en) 2011-10-18

Similar Documents

Publication Publication Date Title
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CR20110099A (es) Pirrolidina-2-carboxamidas sustituidas
CO6430425A2 (es) Compuestos en calidad de antagonistas de bradiquinina b1
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
AR098912A1 (es) Inhibidores de syk
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
AR070648A1 (es) Derivados de bencimidazol sustituido
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
AR066759A1 (es) Derivados de piperidina-amida
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER
AR069306A1 (es) Derivados de metil- bencimidazol como moduladores de receptor x de farnesoide(fxr)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal